Company & Asset Profile
The master record that makes the software contextual, not just a pretty agenda.
BaiOS · Biotech venture planning
Biotech management, done right.
BaiOS is the Biotech Venture Planning platform that turns your science into a living plan — regulatory gates, runway and European funding in one place. Not task management: the system that tells you which milestone to buy with your cash before it runs out.
The problem
A brilliant asset, and no system to turn it into a company.
Early-stage biotech runs on scattered files and a founder wearing every hat. A spreadsheet does not know what a regulatory gate is. BaiOS does.
01
No operator on the plan
The founder runs science, funding and the board update alone, with no CFO, PMO or regulatory lead to hold it together.
02
Cash against unclear milestones
You know how many months of runway are left. You do not know which milestone unlocks the next round, or what it costs.
03
Four plans, four files
Science, regulatory, financial and investor stories live in separate documents with different assumptions.
04
Gates that are just tasks
The roadmap lists activities, not decision gates: no criteria, no dependencies, no go/no-go.
05
The plan dies in a PDF
The deck is rebuilt by hand every 18 months instead of falling out of a living model.
06
European funding is a maze
CDTI, ENISA, EIC, Eurostars, equity and loans — each with its own timing and eligible costs — planned in disconnected spreadsheets.
Milestone-to-Money
How BaiOS connects the gate to the money.
The gate ↔ money relationship is the soul of the product. Change one assumption and the runway, the gates and the funding gap move with it.
Map the asset
One master record — company, asset, indication and a living TPP — so the plan is contextual, not a pretty agenda.
Sequence the gates
Decision gates, not tasks: each carries minimum criteria, evidence, cost, date, dependencies and a RAG status.
Price each milestone
Every milestone is linked to a cost and to the funding it unlocks. "What if the tox study slips six months?" is answered in seconds.
Track the runway
Burn-to-milestone and cash-out date, not vanity burn — a runway that knows what a gate is, recomputed server-side.
Report from the model
The investor update, board pack and CDTI/ENISA report fall out of the same plan. The PDF comes out of the model.
Toxicity study
Preclinical
€185K
▲ on track
PCT filing
Intellectual property
€32K
● pending
Scientific advice meeting
Regulatory · AEMPS
Mar '27
▼ 6 wks
Series A close
Investment
€2.4M
▲ 8% vs plan
The living plan
MilestoneGate criteria · Evidence
CostPrice per gate · Dependencies
RunwayBurn-to-milestone · Cash-out
FundingGrant · Bridge · Round
Modules
Ten modules, one connected model.
Nothing here is independent: a change in the TPP moves the cost, the timeline, the risk and the story with it.
Development Roadmap
A scientific-regulatory roadmap with templates by modality.
Regulatory Gates
The differentiator: decision gates, not regulatory tasks.
Living TPP
A target product profile that is alive, not a dead PDF — the base of every assumption.
Financial Plan & Runway
Beyond cash in, cash out: burn-to-milestone and cash-out date.
Mixed Funding Planner
Equity, grants, loans and BD in one place — the European non-dilutive map US tools ignore.
Scenario Planning
Every assumption automatically impacts cash, milestones and reporting.
Investor & Board Reporting
Investor update, board pack and grant report generated from the data model.
Risk Register
Living risks with runway impact, not a forgotten table.
Adbaio Advisor Layer
Expert judgement embedded in the product: comments, monthly review and next best action.
Positioning
What BaiOS is not.
Every alternative owns one slice of the problem. BaiOS ties gate ↔ money together, with European funding logic and Adbaio advisory built in — which none of them have.
01
Not Asana with a lab coat
Task tools (Asana, Notion, Monday) have no biotech logic: no gates, no TPP, no runway that knows what a milestone is.
02
Not a pharma PPM
Planisware and Planview are a Boeing cockpit for a four-person spin-off.
03
Not an FP&A app
Runway and Pigment don't know what a CTA package is, or which milestone unlocks a Series A.
04
Not regulatory AI
Weave Bio automates documents; it does not plan the company.
05
Not US-only
Orchestra Bio is the closest, but ignores European public funding and is not built for spin-offs.
BaiOS + Adbaio
The software keeps the plan alive. The advisor keeps it right.
Adbaio without BaiOS is a great plan that goes stale in a PDF. BaiOS without Adbaio is eighty empty fields a founder abandons. Together they are a living plan with expert judgement embedded in it — the software retains, the advisory reviews it monthly.
Pricing
One workspace, priced by how far you plan.
Monthly, no lock-in. Prices exclude VAT; 21% is added at checkout for Spanish buyers.
Basic
€220/mo
- One company workspace
- Milestone & runway planning
- Email support
Advanced
€280/mo
- Everything in Basic
- Scenario modelling
- Funding & gate tracking
Pro
€390/mo
- Everything in Advanced
- Advisor collaboration
- Board-ready reports
- Priority support
Your living biotech plan — science, regulation and money in one place.
From scientific hypothesis to the next financeable milestone. Set it up before you pitch, not after: the deck and the data room come out of the model.